Liu Cheng reported option exercise involving 100,000 derivative units of Estrella Immunopharma, Inc. at $0.00 for $0 on Aug 25, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
CEO
CEO
Filed Aug 26, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
100,000Incentive Stock Option
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
900,000Direct
Trade date
Aug 25, 2026Option exercise
Filed
Aug 26, 2026, 7:23 PM ET1-day reporting delay
Accession
0001996255-26-000004Code M · Transaction 103507
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Aug 25, 2026Option exercise100,000$0.82$81,500Trade 103506
2 transaction rows in this filing. Joint filers share the same rows.

ESLA price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ESLA · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago1w ago1d ago
Returns since7d −5.5%30d −34%90d180d1y

Footnotes in full

F1: Represents the exercise price per share paid by the Reporting Person upon the exercise of the stock options reported in Table II. F2: Reflects the 297,437 shares of Common Stock directly beneficially owned as reported on the Reporting Person's most recent Form 4, plus the 100,000 shares acquired upon the reported exercise. F3: Represents incentive share options granted to the Reporting Person on October 30, 2024 under the Issuer's 2023 Omnibus Incentive Plan, of which twenty-five percent (25%) was immediately exercisable on the date of grant, with the remainder vesting in equal monthly installments of 1/48th of the total award on each monthly anniversary of October 30, 2024. The options were vested as to the shares exercised. F4: Not applicable. The reported transaction is the exercise of the stock option for the exercise price set forth in Column 2. No separate consideration was paid or received for the derivative security.